The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress
Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti‐inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through pos...
Gespeichert in:
| Veröffentlicht in: | Drug development research 2019-09, Vol.80 (6), p.714-730 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 730 |
|---|---|
| container_issue | 6 |
| container_start_page | 714 |
| container_title | Drug development research |
| container_volume | 80 |
| creator | Dua, Kamal Wadhwa, Ridhima Singhvi, Gautam Rapalli, Vamshikrishna Shukla, Shakti Dhar Shastri, Madhur D. Gupta, Gaurav Satija, Saurabh Mehta, Meenu Khurana, Navneet Awasthi, Rajendra Maurya, Pawan Kumar Thangavelu, Lakshmi S, Rajeshkumar Tambuwala, Murtaza M. Collet, Trudi Hansbro, Philip M. Chellappan, Dinesh Kumar |
| description | Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti‐inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post‐transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro‐inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases. |
| doi_str_mv | 10.1002/ddr.21571 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2312550186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2299153593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-b5edf7c2f9393c71d089fa4e599f75969008274311ec16e091115db420adbe903</originalsourceid><addsrcrecordid>eNp1kE1LAzEQQIMotlYP_gEJeNHD2kyy6W68id9QFEo9h-xmViPb3Zp0lf57o1s9CJ6Ggceb4RFyCOwMGONja_0ZB5nBFhkCU3nCuVLbZMh4xpNUKBiQvRBeGQNI83yXDARMFAihhsTMX5Au2xU2K2dq2lY0uNnDBS1MQEut756pxdq9o19T11CPYem8WbVxtS603qIP53SGZRRQY99NU2KgprF06dvniId9slOZOuDBZo7I0831_PIumT7e3l9eTJNS5DkkhURbZSWvlFCizMCyXFUmRalUlUk1UYzlPEsFAJYwQaYAQNoi5czYAhUTI3LSe-Phtw7DSi9cKLGuTYNtFzQXwKVkkE8ievwHfW0738Tv9Fc5kEIqEanTnip9G4LHSi-9Wxi_1sD0V3cdu-vv7pE92hi7YoH2l_wJHYFxD3y4Gtf_m_TV1axXfgKX8os0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2299153593</pqid></control><display><type>article</type><title>The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Dua, Kamal ; Wadhwa, Ridhima ; Singhvi, Gautam ; Rapalli, Vamshikrishna ; Shukla, Shakti Dhar ; Shastri, Madhur D. ; Gupta, Gaurav ; Satija, Saurabh ; Mehta, Meenu ; Khurana, Navneet ; Awasthi, Rajendra ; Maurya, Pawan Kumar ; Thangavelu, Lakshmi ; S, Rajeshkumar ; Tambuwala, Murtaza M. ; Collet, Trudi ; Hansbro, Philip M. ; Chellappan, Dinesh Kumar</creator><creatorcontrib>Dua, Kamal ; Wadhwa, Ridhima ; Singhvi, Gautam ; Rapalli, Vamshikrishna ; Shukla, Shakti Dhar ; Shastri, Madhur D. ; Gupta, Gaurav ; Satija, Saurabh ; Mehta, Meenu ; Khurana, Navneet ; Awasthi, Rajendra ; Maurya, Pawan Kumar ; Thangavelu, Lakshmi ; S, Rajeshkumar ; Tambuwala, Murtaza M. ; Collet, Trudi ; Hansbro, Philip M. ; Chellappan, Dinesh Kumar</creatorcontrib><description>Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti‐inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post‐transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro‐inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.</description><identifier>ISSN: 0272-4391</identifier><identifier>EISSN: 1098-2299</identifier><identifier>DOI: 10.1002/ddr.21571</identifier><identifier>PMID: 31691339</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Alveoli ; Animals ; delivery systems ; Drug Carriers - administration & dosage ; Drug delivery ; Drug delivery systems ; Gene expression ; Gene regulation ; Gene therapy ; Humans ; Immune clearance ; Immune response ; Inflammation ; Inhalation ; Inhalers ; Lung diseases ; Macrophages ; miRNA ; nanocarriers ; pulmonary ; Respiration ; Respiratory diseases ; Respiratory Tract Diseases - drug therapy ; Ribonucleic acid ; RNA ; RNA interference ; RNA, Small Interfering - administration & dosage ; RNA-mediated interference ; siRNA ; System effectiveness ; Transcription</subject><ispartof>Drug development research, 2019-09, Vol.80 (6), p.714-730</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-b5edf7c2f9393c71d089fa4e599f75969008274311ec16e091115db420adbe903</citedby><cites>FETCH-LOGICAL-c3881-b5edf7c2f9393c71d089fa4e599f75969008274311ec16e091115db420adbe903</cites><orcidid>0000-0001-7941-0229 ; 0000-0002-7507-1159</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fddr.21571$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fddr.21571$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31691339$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dua, Kamal</creatorcontrib><creatorcontrib>Wadhwa, Ridhima</creatorcontrib><creatorcontrib>Singhvi, Gautam</creatorcontrib><creatorcontrib>Rapalli, Vamshikrishna</creatorcontrib><creatorcontrib>Shukla, Shakti Dhar</creatorcontrib><creatorcontrib>Shastri, Madhur D.</creatorcontrib><creatorcontrib>Gupta, Gaurav</creatorcontrib><creatorcontrib>Satija, Saurabh</creatorcontrib><creatorcontrib>Mehta, Meenu</creatorcontrib><creatorcontrib>Khurana, Navneet</creatorcontrib><creatorcontrib>Awasthi, Rajendra</creatorcontrib><creatorcontrib>Maurya, Pawan Kumar</creatorcontrib><creatorcontrib>Thangavelu, Lakshmi</creatorcontrib><creatorcontrib>S, Rajeshkumar</creatorcontrib><creatorcontrib>Tambuwala, Murtaza M.</creatorcontrib><creatorcontrib>Collet, Trudi</creatorcontrib><creatorcontrib>Hansbro, Philip M.</creatorcontrib><creatorcontrib>Chellappan, Dinesh Kumar</creatorcontrib><title>The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress</title><title>Drug development research</title><addtitle>Drug Dev Res</addtitle><description>Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti‐inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post‐transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro‐inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.</description><subject>Alveoli</subject><subject>Animals</subject><subject>delivery systems</subject><subject>Drug Carriers - administration & dosage</subject><subject>Drug delivery</subject><subject>Drug delivery systems</subject><subject>Gene expression</subject><subject>Gene regulation</subject><subject>Gene therapy</subject><subject>Humans</subject><subject>Immune clearance</subject><subject>Immune response</subject><subject>Inflammation</subject><subject>Inhalation</subject><subject>Inhalers</subject><subject>Lung diseases</subject><subject>Macrophages</subject><subject>miRNA</subject><subject>nanocarriers</subject><subject>pulmonary</subject><subject>Respiration</subject><subject>Respiratory diseases</subject><subject>Respiratory Tract Diseases - drug therapy</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA interference</subject><subject>RNA, Small Interfering - administration & dosage</subject><subject>RNA-mediated interference</subject><subject>siRNA</subject><subject>System effectiveness</subject><subject>Transcription</subject><issn>0272-4391</issn><issn>1098-2299</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LAzEQQIMotlYP_gEJeNHD2kyy6W68id9QFEo9h-xmViPb3Zp0lf57o1s9CJ6Ggceb4RFyCOwMGONja_0ZB5nBFhkCU3nCuVLbZMh4xpNUKBiQvRBeGQNI83yXDARMFAihhsTMX5Au2xU2K2dq2lY0uNnDBS1MQEut756pxdq9o19T11CPYem8WbVxtS603qIP53SGZRRQY99NU2KgprF06dvniId9slOZOuDBZo7I0831_PIumT7e3l9eTJNS5DkkhURbZSWvlFCizMCyXFUmRalUlUk1UYzlPEsFAJYwQaYAQNoi5czYAhUTI3LSe-Phtw7DSi9cKLGuTYNtFzQXwKVkkE8ievwHfW0738Tv9Fc5kEIqEanTnip9G4LHSi-9Wxi_1sD0V3cdu-vv7pE92hi7YoH2l_wJHYFxD3y4Gtf_m_TV1axXfgKX8os0</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Dua, Kamal</creator><creator>Wadhwa, Ridhima</creator><creator>Singhvi, Gautam</creator><creator>Rapalli, Vamshikrishna</creator><creator>Shukla, Shakti Dhar</creator><creator>Shastri, Madhur D.</creator><creator>Gupta, Gaurav</creator><creator>Satija, Saurabh</creator><creator>Mehta, Meenu</creator><creator>Khurana, Navneet</creator><creator>Awasthi, Rajendra</creator><creator>Maurya, Pawan Kumar</creator><creator>Thangavelu, Lakshmi</creator><creator>S, Rajeshkumar</creator><creator>Tambuwala, Murtaza M.</creator><creator>Collet, Trudi</creator><creator>Hansbro, Philip M.</creator><creator>Chellappan, Dinesh Kumar</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7941-0229</orcidid><orcidid>https://orcid.org/0000-0002-7507-1159</orcidid></search><sort><creationdate>201909</creationdate><title>The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress</title><author>Dua, Kamal ; Wadhwa, Ridhima ; Singhvi, Gautam ; Rapalli, Vamshikrishna ; Shukla, Shakti Dhar ; Shastri, Madhur D. ; Gupta, Gaurav ; Satija, Saurabh ; Mehta, Meenu ; Khurana, Navneet ; Awasthi, Rajendra ; Maurya, Pawan Kumar ; Thangavelu, Lakshmi ; S, Rajeshkumar ; Tambuwala, Murtaza M. ; Collet, Trudi ; Hansbro, Philip M. ; Chellappan, Dinesh Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-b5edf7c2f9393c71d089fa4e599f75969008274311ec16e091115db420adbe903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Alveoli</topic><topic>Animals</topic><topic>delivery systems</topic><topic>Drug Carriers - administration & dosage</topic><topic>Drug delivery</topic><topic>Drug delivery systems</topic><topic>Gene expression</topic><topic>Gene regulation</topic><topic>Gene therapy</topic><topic>Humans</topic><topic>Immune clearance</topic><topic>Immune response</topic><topic>Inflammation</topic><topic>Inhalation</topic><topic>Inhalers</topic><topic>Lung diseases</topic><topic>Macrophages</topic><topic>miRNA</topic><topic>nanocarriers</topic><topic>pulmonary</topic><topic>Respiration</topic><topic>Respiratory diseases</topic><topic>Respiratory Tract Diseases - drug therapy</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA interference</topic><topic>RNA, Small Interfering - administration & dosage</topic><topic>RNA-mediated interference</topic><topic>siRNA</topic><topic>System effectiveness</topic><topic>Transcription</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dua, Kamal</creatorcontrib><creatorcontrib>Wadhwa, Ridhima</creatorcontrib><creatorcontrib>Singhvi, Gautam</creatorcontrib><creatorcontrib>Rapalli, Vamshikrishna</creatorcontrib><creatorcontrib>Shukla, Shakti Dhar</creatorcontrib><creatorcontrib>Shastri, Madhur D.</creatorcontrib><creatorcontrib>Gupta, Gaurav</creatorcontrib><creatorcontrib>Satija, Saurabh</creatorcontrib><creatorcontrib>Mehta, Meenu</creatorcontrib><creatorcontrib>Khurana, Navneet</creatorcontrib><creatorcontrib>Awasthi, Rajendra</creatorcontrib><creatorcontrib>Maurya, Pawan Kumar</creatorcontrib><creatorcontrib>Thangavelu, Lakshmi</creatorcontrib><creatorcontrib>S, Rajeshkumar</creatorcontrib><creatorcontrib>Tambuwala, Murtaza M.</creatorcontrib><creatorcontrib>Collet, Trudi</creatorcontrib><creatorcontrib>Hansbro, Philip M.</creatorcontrib><creatorcontrib>Chellappan, Dinesh Kumar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Drug development research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dua, Kamal</au><au>Wadhwa, Ridhima</au><au>Singhvi, Gautam</au><au>Rapalli, Vamshikrishna</au><au>Shukla, Shakti Dhar</au><au>Shastri, Madhur D.</au><au>Gupta, Gaurav</au><au>Satija, Saurabh</au><au>Mehta, Meenu</au><au>Khurana, Navneet</au><au>Awasthi, Rajendra</au><au>Maurya, Pawan Kumar</au><au>Thangavelu, Lakshmi</au><au>S, Rajeshkumar</au><au>Tambuwala, Murtaza M.</au><au>Collet, Trudi</au><au>Hansbro, Philip M.</au><au>Chellappan, Dinesh Kumar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress</atitle><jtitle>Drug development research</jtitle><addtitle>Drug Dev Res</addtitle><date>2019-09</date><risdate>2019</risdate><volume>80</volume><issue>6</issue><spage>714</spage><epage>730</epage><pages>714-730</pages><issn>0272-4391</issn><eissn>1098-2299</eissn><abstract>Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti‐inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post‐transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro‐inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>31691339</pmid><doi>10.1002/ddr.21571</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0001-7941-0229</orcidid><orcidid>https://orcid.org/0000-0002-7507-1159</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0272-4391 |
| ispartof | Drug development research, 2019-09, Vol.80 (6), p.714-730 |
| issn | 0272-4391 1098-2299 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2312550186 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Alveoli Animals delivery systems Drug Carriers - administration & dosage Drug delivery Drug delivery systems Gene expression Gene regulation Gene therapy Humans Immune clearance Immune response Inflammation Inhalation Inhalers Lung diseases Macrophages miRNA nanocarriers pulmonary Respiration Respiratory diseases Respiratory Tract Diseases - drug therapy Ribonucleic acid RNA RNA interference RNA, Small Interfering - administration & dosage RNA-mediated interference siRNA System effectiveness Transcription |
| title | The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A04%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20potential%20of%20siRNA%20based%20drug%20delivery%20in%20respiratory%20disorders:%20Recent%20advances%20and%20progress&rft.jtitle=Drug%20development%20research&rft.au=Dua,%20Kamal&rft.date=2019-09&rft.volume=80&rft.issue=6&rft.spage=714&rft.epage=730&rft.pages=714-730&rft.issn=0272-4391&rft.eissn=1098-2299&rft_id=info:doi/10.1002/ddr.21571&rft_dat=%3Cproquest_cross%3E2299153593%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2299153593&rft_id=info:pmid/31691339&rfr_iscdi=true |